Search Results
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Wei Deng in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St.Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Merete Krogh in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
Introduction High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are defined by the presence of neuroendocrine phenotype and a high proliferation rate (Ki-67 > 20%). The HG NEN entity consists of well
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St. Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Lene W Vestermark in
Google Scholar
PubMed
Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Morten Ladekarl in
Google Scholar
PubMed
Search for other papers by Elizaveta Mitkina Tabaksblat in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) constitute ~2% of all malignancies and are frequently located in the gastrointestinal (GI) tract and pancreas. High-grade gastroenteropancreatic (HG-GEP) NENs are among the most aggressive cancers
Search for other papers by Jennifer R Eads in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Tim Asmis in
Google Scholar
PubMed
Search for other papers by Andrew M Bellizzi in
Google Scholar
PubMed
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Michael Frumovitz in
Google Scholar
PubMed
Search for other papers by Joshua Meyer in
Google Scholar
PubMed
Search for other papers by Erik Mittra in
Google Scholar
PubMed
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Search for other papers by Eric Nakakura in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Heloisa P Soares in
Google Scholar
PubMed
Search for other papers by Brian Untch in
Google Scholar
PubMed
Search for other papers by Namrata Vijayvergia in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
management of high-grade NENs of gastroenteropancreatic and gynecologic origin. Methods for developing consensus practice recommendations A panel consisting of 17 neuroendocrine experts from 13 institutions was convened by the NANETS Publications and
Search for other papers by Tobias Hofving in
Google Scholar
PubMed
Search for other papers by Viktor Sandblom in
Google Scholar
PubMed
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Emman Shubbar in
Google Scholar
PubMed
Search for other papers by Gülay Altiparmak in
Google Scholar
PubMed
Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by John Swanpalmer in
Google Scholar
PubMed
Search for other papers by Bilal Almobarak in
Google Scholar
PubMed
Search for other papers by Anna-Karin Elf in
Google Scholar
PubMed
Search for other papers by Viktor Johanson in
Google Scholar
PubMed
Search for other papers by Erik Elias in
Google Scholar
PubMed
Search for other papers by Erik Kristiansson in
Google Scholar
PubMed
Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Eva Forssell-Aronsson in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
months) in patients with small intestinal neuroendocrine tumours (SINETs), compared with the best standard of care ( Strosberg et al. 2017 ). This has led to an FDA approval of 177 Lu-octreotate therapy for gastroenteropancreatic NETs and its inclusion
Search for other papers by Tobias Hofving in
Google Scholar
PubMed
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Bilal Almobarak in
Google Scholar
PubMed
Search for other papers by Linda Inge in
Google Scholar
PubMed
Search for other papers by Roswitha Pfragner in
Google Scholar
PubMed
Search for other papers by Marta Persson in
Google Scholar
PubMed
Search for other papers by Göran Stenman in
Google Scholar
PubMed
Search for other papers by Erik Kristiansson in
Google Scholar
PubMed
Search for other papers by Viktor Johanson in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 100 1282 – 1289 . ( https://doi.org/10.1093/jnci/djn275 ) 18780869 10.1093/jnci/djn275 Perren A Komminoth P Saremaslani P Matter C Feurer S Lees JA Heitz PU Eng C 2000
Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Dimitrios Papantoniou in
Google Scholar
PubMed
Search for other papers by Malin Grönberg in
Google Scholar
PubMed
Search for other papers by Espen Thiis-Evensen in
Google Scholar
PubMed
University of Bergen, Deptartment of Clinical Medicine, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Surgery, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Kalle Landerholm in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Eva Tiensuu Janson in
Google Scholar
PubMed
C Schade-Brittinger C Barth P Moll R 2005 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial . Clinical Gastroenterology and Hepatology 3 761 – 771 . ( https://doi.org/10.1016/S
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Stavroula Antoniou in
Google Scholar
PubMed
Search for other papers by George Kanakis in
Google Scholar
PubMed
Search for other papers by Nikolaos Economopoulos in
Google Scholar
PubMed
Search for other papers by Dimitra Rontogianni in
Google Scholar
PubMed
Search for other papers by Anastasios Ntavatzikos in
Google Scholar
PubMed
Search for other papers by Nikolaos Tsavaris in
Google Scholar
PubMed
Search for other papers by Dimitrios Pectasides in
Google Scholar
PubMed
Search for other papers by George Dimitriadis in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Downstaging of gastroenteropancreatic tumours (arrows) after TeBeSa combination therapy. MRI details shown before treatment (a) and (c) and after six cycles (b) and (d) for two patients with a pancreatic (a)/(b) and a duodenal tumour (c)/(d). During the past 4
Search for other papers by Paula Fontes Asprino in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Rudinei Diogo Marques Linck in
Google Scholar
PubMed
Search for other papers by Jônatas Cesar in
Google Scholar
PubMed
Search for other papers by Florêncio Porto Freitas in
Google Scholar
PubMed
Search for other papers by Fernanda Christtanini Koyama in
Google Scholar
PubMed
Search for other papers by Rachel Simões Pimenta Riechelmann in
Google Scholar
PubMed
Search for other papers by Frederico Perego Costa in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Paulo Marcelo Gehm Hoff in
Google Scholar
PubMed
Search for other papers by Pedro Alexandre Favoretto Galante in
Google Scholar
PubMed
Search for other papers by Diogo Meyer in
Google Scholar
PubMed
Search for other papers by Anamaria Aranha Camargo in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Jorge Sabbaga in
Google Scholar
PubMed
, epidemiological studies have demonstrated that non-syndromic individuals with an affected relative are at an increased risk of developing gastroenteropancreatic (GEP) NENs. In individuals with affected siblings, the relative risk of GEP NEN increases by 13.4-fold
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Francesco Barretta in
Google Scholar
PubMed
Search for other papers by Annalisa Trama in
Google Scholar
PubMed
Search for other papers by Laura Botta in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Roberto Buzzoni in
Google Scholar
PubMed
University of Milan, Milan, Italy
Search for other papers by Filippo De Braud in
Google Scholar
PubMed
Liver Surgery, Transplantation and Gastroenterology, University of Milan and Istituto Nazionale Tumori Fondazione IRCCS, ENETS Center of Excellence, Milano, Milan, Italy
Search for other papers by Vincenzo Mazzaferro in
Google Scholar
PubMed
Search for other papers by Ugo Pastorino in
Google Scholar
PubMed
Search for other papers by Ettore Seregni in
Google Scholar
PubMed
Search for other papers by Luigi Mariani in
Google Scholar
PubMed
Search for other papers by Gemma Gatta in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Daniela Femia in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Francesco Panzuto in
Google Scholar
PubMed
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Maria Pia Brizzi in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Laura Catena in
Google Scholar
PubMed
Search for other papers by Harry Comber in
Google Scholar
PubMed
Search for other papers by Fiona Dwane in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Dario Giuffrida in
Google Scholar
PubMed
Search for other papers by Kris Henau in
Google Scholar
PubMed
Search for other papers by Toni Ibrahim in
Google Scholar
PubMed
Search for other papers by Riccardo Marconcini in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Maja Primic Žakelj in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Elizabeth Van Eycken in
Google Scholar
PubMed
Search for other papers by Jan Maaten Van der Zwan in
Google Scholar
PubMed
Search for other papers by Tina Žagar in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Rosalba Miceli in
Google Scholar
PubMed
Search for other papers by NEPscore Working Group in
Google Scholar
PubMed
Tumor Society (ENETS) Center of Excellence for the treatment of gastroenteropancreatic (GEP)-NETs; (ii) a European external validation cohort, which comprised rare NET patients included in the database of the pilot study of the European project
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Josh Mailman in
Google Scholar
PubMed
Search for other papers by Michael W Rabow in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Sarah Creed in
Google Scholar
PubMed
Search for other papers by Hagen F Kennecke in
Google Scholar
PubMed
Search for other papers by Janice Pasieka in
Google Scholar
PubMed
Search for other papers by Jennifer Zuar in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
, ease of administration, and tolerability, SSAs are generally considered as first-line therapeutic option in well-differentiated gastroenteropancreatic NETs (GEP-NETs). The role of continuing SSAs after disease progression is debatable ( Strosberg et al